Neurocrine Biosciences (NBIX) News Today $127.31 +2.43 (+1.95%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$127.54 +0.23 (+0.18%) As of 08:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive DyskinesiaJune 20 at 8:30 AM | prnewswire.comSowell Financial Services LLC Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Sowell Financial Services LLC bought a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,786 shares of the company's stock, valued at approJune 20 at 4:03 AM | marketbeat.comPallas Capital Advisors LLC Reduces Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Pallas Capital Advisors LLC lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 66.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,600 shares ofJune 14, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by BrokeragesNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-two analysts that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation andJune 14, 2025 | marketbeat.comNeurocrine Biosciences' SWOT analysis: biotech stock balances Ingrezza success with pipeline potentialJune 14, 2025 | investing.comStanley Laman Group Ltd. Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Stanley Laman Group Ltd. trimmed its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 22.5% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,659 shares of the company's stock after selling 9,499 shareJune 13, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by TobamTobam reduced its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 29.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 22,012 shares of the company's stock after selling 9,256 shares during the quarter. TobaJune 13, 2025 | marketbeat.comAssenagon Asset Management S.A. Buys 367,315 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Assenagon Asset Management S.A. lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1,405.2% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 393,455 shares of the company's stock after acquiring an additioJune 13, 2025 | marketbeat.comHandelsbanken Fonder AB Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Handelsbanken Fonder AB grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 220.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 86,067 shares of the company's stock after pJune 13, 2025 | marketbeat.comDavis Investment Partners LLC Purchases New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Davis Investment Partners LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,619 shares of the company's stock, valued atJune 12, 2025 | marketbeat.comCantor Fitzgerald Weighs in on NBIX FY2026 EarningsJune 12, 2025 | americanbankingnews.comSG Americas Securities LLC Grows Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)SG Americas Securities LLC boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 16,436.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 175,613 shares of the company's stock after buyingJune 11, 2025 | marketbeat.comNeurocrine Biosciences, Inc.: Neurocrine Biosciences Appoints Lewis Choi as Chief Information OfficerJune 10, 2025 | finanznachrichten.deAnalysts Issue Forecasts for NBIX FY2026 EarningsNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Neurocrine Biosciences in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of $6June 10, 2025 | marketbeat.comCongress Asset Management Co. Acquires New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Congress Asset Management Co. purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,363 shares of the company's stock, valued atJune 10, 2025 | marketbeat.comNeurocrine Biosciences Appoints Lewis Choi as Chief Information Officer | NBIX stock newsJune 9, 2025 | gurufocus.comNeurocrine Biosciences Appoints Lewis Choi as Chief Information Officer | NBIX Stock NewsJune 9, 2025 | gurufocus.comNeurocrine Biosciences (NBIX) Appoints Lewis Choi as CIO | NBIX Stock NewsJune 9, 2025 | gurufocus.comNeurocrine Biosciences names new Chief Information OfficerJune 9, 2025 | investing.comNeurocrine Biosciences Appoints Lewis Choi as Chief Information OfficerJune 9, 2025 | prnewswire.comGuggenheim Maintains Buy Rating on Neurocrine Biosciences Following Investor MeetingJune 6, 2025 | msn.comWealth Enhancement Advisory Services LLC Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Wealth Enhancement Advisory Services LLC raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 199.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,886 shares of the comJune 6, 2025 | marketbeat.comRhumbline Advisers Has $34.78 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Rhumbline Advisers lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 314,486 shares of the company's stock after selling 5,9June 5, 2025 | marketbeat.comGAMMA Investing LLC Grows Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)GAMMA Investing LLC boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 9,446.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 219,099 sharesJune 5, 2025 | marketbeat.comNxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568June 2, 2025 | globenewswire.comNeurocrine Biosciences' (NBIX) "Outperform" Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and issued a $145.00 price objective on shares of Neurocrine Biosciences in a research report on Monday.June 2, 2025 | marketbeat.comNeurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO™ Study Demonstrating INGREZZA® (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive DyskinesiaJune 2, 2025 | prnewswire.comSummit Global Investments Sells 21,182 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Summit Global Investments cut its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 66.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,878 shares of the companyJune 1, 2025 | marketbeat.comCentral Pacific Bank Trust Division Decreases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Central Pacific Bank Trust Division reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 56.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,625 shares of the company's stocJune 1, 2025 | marketbeat.comFirst Hawaiian Bank Has $724,000 Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)First Hawaiian Bank reduced its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 46.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,550 shares of the company's stock after sellJune 1, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Purchases New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 68,029 shares of the company's stock,June 1, 2025 | marketbeat.comKevin Charles Gorman Sells 9,613 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) Director Kevin Charles Gorman sold 9,613 shares of the business's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total transaction of $1,157,212.94. Following the transaction, the director now directly owns 514,596 shares of the company's stock, valued at approximately $61,947,066.48. This represents a 1.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.May 31, 2025 | marketbeat.comCalifornia State Teachers Retirement System Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)California State Teachers Retirement System lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 136,549 shares of the company's stock after purchasing an addMay 31, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman Sells 9,613 SharesMay 30, 2025 | insidertrades.comLansforsakringar Fondforvaltning AB publ Buys New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Lansforsakringar Fondforvaltning AB publ bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 32,446 shares of the company'May 30, 2025 | marketbeat.comSiemens Fonds Invest GmbH Buys Shares of 6,225 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Siemens Fonds Invest GmbH bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 6,225 shares of the company's stock, valued at approximately $850May 30, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Has $5.53 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Public Employees Retirement System of Ohio trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 5.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,518 shares ofMay 30, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Two Sigma Investments LPTwo Sigma Investments LP lowered its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 70.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,771 shares of the company's stock afMay 30, 2025 | marketbeat.comDirector Kevin Gorman Sells 9,613 Shares of Neurocrine Biosciences Inc (NBIX)May 29, 2025 | gurufocus.comMackenzie Financial Corp Has $7.54 Million Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Mackenzie Financial Corp lowered its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 36.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 55,221 shares of the company's stock after selling 31,362 shareMay 29, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NBIX)’s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 LaunchedMay 29, 2025 | insidermonkey.comNxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025May 28, 2025 | investing.comNxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025May 28, 2025 | globenewswire.comNeurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025May 28, 2025 | prnewswire.comGF Fund Management CO. LTD. Purchases New Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)GF Fund Management CO. LTD. purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 2,126 shares of the company's stock, valued at approximately $290,000. A number of otherMay 27, 2025 | marketbeat.comTidal Investments LLC Lowers Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Tidal Investments LLC cut its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 37.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,425 shares of the company's stock after selliMay 27, 2025 | marketbeat.comPeak Retirement Planning Inc. Purchases New Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Peak Retirement Planning Inc. purchased a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 7,630 shares of the company's stock, valueMay 26, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 19.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,070,0May 26, 2025 | marketbeat.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Position Lowered by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lessened its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,206 shares of the company's stock after selling 2May 26, 2025 | marketbeat.comCetera Investment Advisers Purchases 2,593 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)Cetera Investment Advisers raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 46.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,169 shares of the company's stoMay 25, 2025 | marketbeat.com Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Media Mentions By Week NBIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NBIX News Sentiment▼1.590.69▲Average Medical News Sentiment NBIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NBIX Articles This Week▼616▲NBIX Articles Average Week Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Today Biogen News Today Incyte News Today United Therapeutics News Today Exelixis News Today BioMarin Pharmaceutical News Today Exact Sciences News Today Repligen News Today Halozyme Therapeutics News Today Madrigal Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NBIX) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredWar-Proof Power Why This "Weird" Government Land Auction Was No Ordinary Sale When 218,000 acres of land... smack in the m...Stansberry Research | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBIX Stock Free NBIX Stock Alerts